Metastasis is the primary cause of death in prostate cancer (PCa) patients. Effective therapeutic intervention in metastatic PCa is undermined by our poor understanding of its molecular aetiology. Defining the mechanisms underlying PCa metastasis may lead to insights into how to decrease morbidity and mortality in this disease. Glyoxalase 1 (Glo1) is the detoxification enzyme of methylglyoxal 
acids and proteins to form the heterogeneous family of advanced glycation end products (AGEs). 5 MG-derived dicarbonyl adducts exert complex pleiotropic effects, including modulation of protein biological activity 6 and stability, 7 generation of reactive oxygen species and oxidative stress, 8, 9 which may culminate in distinct biological outcomes. [9] [10] [11] [12] [13] [14] Hydroimidazolone (MG-H1) and argpyrimidine (AP) are major AGEs formed by spontaneous reaction between MG and protein arginine residues. 15 The levels of MG-derived AGEs, as well as of AGEs generated by the reaction of the free amino groups of N-terminal amino acids with carbonyl groups of reducing sugars, have been investigated in different human cancer tissues. [16] [17] [18] Results from these studies suggest that the expression pattern of AGEs can be tumour specific 16 and that their accumulation in cancer tissues may be linked to tumour aggression. 19 Specifically, in PCa, accumulation of a specific AGE (carboxymethyl lysine, CML) has been recently found in malignant compared with normal tissues where it positively correlates with tumour aggressiveness. 20 AGEs function as ligand activators for the transmembrane receptor for AGEs (RAGE) 21 which is overexpressed in a variety of human tumours, including PCa. [20] [21] [22] [23] Intriguingly, recent data demonstrate that RAGE can regulate Glo1 expression at both mRNA and protein levels. 24 Glo1 is overexpressed in several human cancers, 5 where it represents an important tumour survival strategy by preventing accumulation of cytotoxic MG, thereby suppressing MG-mediated glycation reactions leading to AGE formation. In PCa, we and others have previously shown that Glo1 plays a major role in the progression of this neoplasia. 25, 26 In particular, in highly invasive and metastatic human PC3 PCa cells, Glo1 acts as a pro-survival factor by eluding apoptosis in a mechanism involving AP and NF-kB signalling pathway. 27 An important determinant of metastasis is the epithelial-tomesenchymal transition (EMT), a dynamic transdifferentiation during which cells acquire a migratory and invasive phenotype. 28 The mechanisms that control the process of EMT in cancer cells are complex and still emerging. In PCa, several key factors contributing to EMT 29 have recently been identified; transforming growth factor beta (TGFb) and miRNAs 30 have been shown to play a crucial role. In addition,
we have recently demonstrated that the Glo1/AP axis can control EMT in a human bronchial model. 11 The possible role of the Glo1/ AP axis in the control of EMT in metastatic PCa has never been investigated. Understanding this circuit in the context of PCa might identify Glo1 as a novel therapeutic target for this lethal stage of the disease. Hence, in this study, we studied whether and how Glo1 might sustain PCa metastatic phenotype as part of the molecular events associated with EMT in DU145 and PC3 human PCa cell lines, models of metastatic PCa. Moreover, to examine this regulatory circuit in a clinically relevant setting, we measured the circulating levels of some of the involved molecules in patients with metastatic compared with non-metastatic PCa. Finally, we examined the capacity of metformin, a widely used anti-diabetic drug and an emerging anti-cancer drug, especially in the field of urologic oncology, [31] [32] [33] to inhibit the EMT-based metastatic phenotype, through control of Glo1 and miR-101 in both PCa cell lines.
| MATERIALS AND METHODS

| Materials
Tissue culture media, foetal bovine serum, penicillin/streptomycin, BCA kit and Laemmli buffer were from ThermoFisher Scientific (Milan, Italy); Roti-Block was from Roth (Germany). Primary antibodies against Glo1, MMP-2, MMP-9, Smad4, lamin b and b-actin were from DBA (Milan, Italy); primary antibodies against E-cadherin (E-cad), zonula occludens-1 (ZO-1), vimentin (Vim), N-cadherin (N-cad), Snail, TGF-b1, phospho-Smad2, phospho-Smad3 and total Smad2 or Smad3 were from Cell Signalling Technology (Danvers, MA, USA). Anti-AP mAb was from Antibodies-online GmbH (Aachen, Germany). The ELISA kit for human TGF-b1 was purchased from R&D Systems (Milan, Italy). The ELISA kit for MG-H1
was from DBA (Milan, Italy). Aminoguanidine bicarbonate (AG), a scavenger of free MG 34 (1 mmol/L, for 3 hours), and metformin (5, 10 and 20 mmol/L for 48 hours) were from Sigma-Aldrich (Milan, Italy). The TGF-b type I receptor inhibitor 35, 36 
SB431542
(0.5 lmol/L for 1 hour) was from Tocris (Milan, Italy). Control cells for the experiments with agents dissolved in non-aqueous solvents showed no significant difference with respect to control cells in RPMI-1640 medium; therefore, all the relative treatments were compared with these latter controls. The biochemical evidence supporting the efficacy of the inhibitors and scavenging agents used in this study was always tested in preliminary experiments, whenever appropriate (data not shown).
| Cell lines and cell culture conditions
The human brain metastasis-derived DU145 and bone metastasisderived PC3 cancer cell lines were obtained from the American Type Culture Collection (ATCC) and cultured as per the suppliers' recommendations at 37°C and 5% CO 2 . 
| Patients
| RNA isolation, reverse transcription and qRT-PCR analysis
RNA isolation, reverse transcription and qRT-PCR analysis were performed as previously described. 10, 27 Briefly, total cellular RNA was iso- 
| Glyoxalase 1 enzyme activity
The activity of Glo1 was assessed as previously described in lysates either from cell lines 40 or from red blood cells. [41] [42] [43] Glo1 enzymatic activity was assayed by an established method. 44 blotting and spectrophotometric assay, or qRT-PCR, respectively ( Figure 1A ). The same experimental design was used for glyoxalase 2 (Glo2) gene silencing (data not shown). Mock transfection was performed to control potential effects due to the transfection reagent. As no significant differences were found between siCtr-or mock-treated and non-transfected cells on the biological phenomena under investigation ( Figure S1 ) in either DU145 or PC3 cells, the observed changes were shown with respect only to siCtrexposed cells.
| Ectopic expression of Glo1 and Glo2
Cells were infected with a transfection-ready plasmid-encoding Glo1 (pCMV-Glo1) or Glo2 (pCMV-Glo2) or control DNA plasmid (pCMV-Ctr), according to the manufacturer's instructions (OriGene, Tema Ricerca, Bologna, Italy).
| Transwell migration and invasion assays
Transwell migration and invasion assays were carried out as described by Malkoski et al. 46 Briefly, transwell assays were con- The histograms indicate mean AE SD of three different cultures, and each was tested in triplicate. Distance scale is 10 lm. siCtr: control (nonspecific siRNA). **P < .01, ***P < .001 vs siCtr cells
| Gelatin zymography
Gelatin zymography was performed according to Shin et al. 48 Briefly, the protein lysates were denatured by mixing 59 gel-load- 
| Immunofluorescence microscopy
Immunofluorescence for F-actin detection was performed as previously described. 11, 49 Briefly, the cells grown on a coverslip were fixed in 3.7% paraformaldehyde, permeabilized in 0.1% Triton X-100
and treated with phalloidin-tetramethylrhodamine B isothiocyanate Therefore, we studied whether Glo1 could sustain DU145 and PC3 metastatic phenotype via EMT control. To this end, EMT was studied by analysing the expression of E-cad and ZO-1, markers of epithelial cells, vimentin and N-cad, markers of mesenchymal cells, Snail, a crucial transcription factor involved in EMT of PCa cells 58 and MMP-2 and MMP-9, whose mRNA and protein are found at increased levels in the serum and tissue samples from PCa patients and are correlated with metastatic disease. 59 As shown in Figure 1C , Glo1 silenced (siGlo1) DU145 and PC3 cells were characterized by increased expression of E-cad and ZO-1 and concurrently decreased expression of vimentin, N-cad and Snail compared with siCtr cells.
Moreover, Glo1 silencing reduced MMP-2 and MMP-9 protein expression and activity, while these remained unaffected in siCtrtreated DU145 or PC3 cells ( Figure 1D ). Finally, Glo1 silencing also resulted in the reorganization of the cytoskeleton ( Figure 1E ). In particular, immunofluorescence staining of F-actin showed a clear decrease in staining intensity and reduction of actin stress fibres in siGlo1-treated compared with siCtr-treated DU145 and PC3 cells ( Figure 1E ). Collectively, our findings showed that Glo1 sustained the metastatic phenotype of the human DU145 and PC3 PCa cell lines by EMT control.
3.2 | Glo1-dependent control of EMT occurs via hydroimidazolone (MG-H1) and AP depletion in DU145 and PC3 cells
To investigate a possible mechanism by which Glo1 sustained the metastatic phenotype of DU145 and PC3 cells via EMT control, we focused on MG-H1 and AP, AGEs generated from the spontaneous modification of arginine residues 15 by MG, the substrate of Glo1.
Besides, AP, like other AGEs, has been reported to be involved in EMT control in a context-dependent manner. 11, 60 With an ELISA kit specific to MG-H1 and an antibody specific to AP-modified residues to use in Western blotting, we detected the intracellular levels of these two adducts. As illustrated in Figure 2A , compared with siCtr cells, siGlo1 treatment induced MG-H1 and AP accumulation in both DU145 and PC3 cells. In particular, as to AP immunodetection, we observed a major band with an approximate molecular weight of 40 kD whose intensity was markedly increased by siGlo1 treatment.
To further test the hypothesis that MG-H1 and AP play a key role in the phenotypic changes associated with siRNA-mediated Glo1 depletion, we next examined the effect of AG, a scavenger of free MG, 61 on various aspects of the EMT phenotype lost upon siGlo treatment.
Thus, as depicted in Figure 2 , upon Glo1 silencing, AG exposure was able to restore the EMT-associated phenotype, at the level of translocates to the nucleus, binds to DNA and regulates transcription of specific genes, such as Snail, a key transcription factor that promotes migration and invasion of cancer cells, including PCa. 63 To address the possible role of the TGF-b1 signalling pathway in the induction of EMT by Glo1-dependent MG-H1 and AP depletion, we studied the nuclear translocation of Smad4, the central mediator of TGF-b1-induced EMT. 64 Thus, in PC3 cells, we found that upon siGlo1 silencing, mRNA ( Figure 3A ), protein expression ( Figure 3B) or secretion ( Figure 3C ) of TGF-b1 and Smad4 activation ( Figure 3D) were all significantly inhibited compared with control (siCtr) cells.
Moreover, pre-treatment with AG restored TGF-b1 expression (Figure 3A ,B,C) and Smad4 activation ( Figure 3D ) to the control levels, indicating that in metastatic PC3 cells, Glo1-dependent MG-H1 and AP depletion was able to drive TGF-b1/SMAD4 signalling pathway.
No differences were observed between siCtr and untreated (Ctr) cells (data not shown). We then wanted to assess whether TGF-b1/ Smad4 signalling was required for the phenotypic changes to PCa cells upon Glo1 knock-down by the TGFb1, inhibitor SB431542.
Thus, under Glo1 knock-down, the inhibition of TGF-b1 signalling by showed that like TGFb1, these EMT-associated proteins were not subject to MG modification to form AP (data not shown). 
| Glo1 sustains PCa cell metastatic phenotype in cooperation with glyoxalase 2
Glo1, together with Glo2, and a catalytic amount of reduced glutathione (GSH), belongs to the glyoxalase system. 71 In this To examine whether the apparent regulatory circuit we had uncovered in PCa cell lines might be mirrored in a clinically relevant setting, we next measured circulating levels of Glo1, MG-H1, AP, miR-101
and TGF-b in patients with metastatic and non-metastatic PCa. In support of the results from the in vitro mechanistic study, we found that patients with metastatic PCa had significantly higher levels of Glo1 and TGF-b1 and markedly lower levels of MG-H1, AP and miR-101 compared with patients exhibiting non-metastatic PCa (Table 2) .
Moreover, a positively significant correlation was found between Glo1 and TGF-b1 (Spearman's correlation coefficient = .84, P = .0012), and a negative correlation was found between Glo1 and MG-H1 or AP or miR-101 (Spearman's correlation coefficient = À.623 and À.640 and À.784; P = 0.012 and P = .010 and P = .005, respectively) in the metastatic group.
| Metformin affects DU145 and PC3 cell metastatic phenotype, inhibits Glo1 and induces miR-101 expression
Metformin is the most widely used anti-diabetic drug in the world, 31 but there is increasing evidence of its potential efficacy as an anticancer drug. 31 In particular, recent studies have suggested that F I G U R E 5 Glyoxalase 1 (Glo1) drives epithelial-to-mesenchymal transition (EMT), migration/invasion and MMP-2/MMP-9 activity under miR-101 control in DU145 and PC3 cells. Effect of miR-101 overexpression (pCMV-MiR-101) and miR-101 inhibition on (A, B) Glo1 expression, at transcript and functional levels, evaluated by qRT-PCR and spectrophotometric analysis, respectively, (C) EMT, evaluated by Western blot analysis of the epithelial marker E-cadherin (E-cad) and the mesenchymal marker vimentin (Vim), (D) migration/invasion capabilities, evaluated by specific assays, and (E) MMP-2/MMP-9 activity, evaluated by zymography, in both DU145 and PC3 cells. The Western blots were obtained by the appropriate Abs. The blots were stripped off the bound Abs and reprobed with anti-b-actin to confirm equal loading. The Western blots shown are representative of three independent experiments. The histograms indicate mean AE SD of three different cultures, and each was tested in triplicate. *P < .05, **P < .01, ***P < .001 vs controls (pCMV-Ctr or miR-Scr) metformin may have benefits especially in the field of urologic oncology. 32, 33 It has been reported that Glo1 can be inhibited by metformin in endometrial cancer cells 72, 73 and that miR-101, typically lost in pancreatic cancer, can be re-expressed following metformin treatment, and in this setting, it is associated with inhibition of cell proliferation, cell migration and invasion, and self-renewal capacity of cancer stem cells. 74 Therefore, we wanted to investigate whether metformin could also down-regulate Glo1 and up-regulate miR-101 in our models and whether these changes might be causally linked with the rescue of the metastatic phenotype of DU145 and PC3 cells in terms of EMT, migration and invasion. In PC3 cells, we found that metformin significantly inhibited Glo1 expression ( Figure 8A ) and increased miR-101 expression ( Figure 8B ) in a dose-dependent manner compared with untreated control cells. Moreover, this was associated with a reversal of EMT ( Figure 8C ), decreased MMP-2/MMP-9 expression ( Figure 8D ), as well as decreased migratory and invasive potential (Figure 8E ). More importantly, following metformin administration, miR-101 inhibition restored Glo1 activity and migration/invasion (Figure 8F) , and similarly, Glo1 overexpression did ( Figure 8G ). Similar results were obtained in DU145 cells ( Figure S7 ).
| DISCUSSION
The dissemination of PCa is a common, incurable aspect of the advanced disease and the primary cause of death in PCa patients.
Prevention and treatment of this terminal phase of PCa require improved understanding of its molecular aetiology to obtain more insights into how to decrease morbidity and mortality in this disease.
In the present study, we have, for the first time, demonstrated that In diabetes-associated renal diseases, AGEs can induce EMT, 59 while in alveolar epithelial cells, AGEs can prevent EMT. 11, 75 In PCa, to our knowledge, the role of AGEs in EMT had not hitherto been investigated. Our findings suggest that the specific MG-derived AGEs, AP and MG-H1, can play a protective role against EMT because their depletion, by Glo1, can promote cell transformation, thus supporting that part of the literature describing a similar role in other contexts. 11, 75 In line with this, Glo1 would act in our PCa cell models as an oncoprotein, in agreement with others. [76] [77] [78] [79] However, a study aimed at functionally identifying tumour suppressor genes in liver cancer identified and validated Glo1 as a tumour suppressor gene;
knock-down of Glo1 by shRNAs increased tumour growth in a mouse model. 80 A similar role has been more recently described by Nokin et al. 81 Therefore, Glo1 would appear to be a dual mediator in tumorigenesis and cancer progression, acting both as an oncogene and as a tumour suppressor, and it can be expected that different cancer types with different backgrounds and, for instance, different MG detoxification rates would react differently to MG stress. Here, we found that Hsp40 was specifically targeted by MG to form AP in both DU145 and PC3 cells. Hsps are a family of proteins that serve as molecular chaperones preventing the formation of non-specific protein aggregates and controlling normal protein folding. 82 Recent evidence also suggests that Hsps are actively involved in tumour cell proliferation, invasion, differentiation, metastases and cell death. 82 In particular, Hsp40 represents a large and understudied family of cochaperones, and in recent years, the possible involvement of the Hsp40 family in tumorigenesis and malignant processes has been proposed. 82 For example, in hepatocellular carcinoma, a member of Hsp40 family promotes tumour progression through induction of EMT, 83 while in lung cancer cells, the expression of another member of the same family inversely correlates with invasion and metastasis, and accordingly, a direct correlation with E-cadherin expression was observed. 84, 85 In line with these latter studies, we identified a protective role for Hsp40-modified AP with respect to EMT, as shown by the treatment with the MG scavenger, AG, which induced the rescue of metastatic phenotype under Glo1 silencing, and an inverse correlation with invasion and migration. In addition to AP-modified Hsp40, other polypeptides that formed AP by Western blot (Figure 2B ) and immunoaffinity purification (data not shown) were MMPs are a family of endopeptidases required for extracellular matrix degradation. Among MMPs, MMP-2 and MMP-9 play important roles for basement membrane type IV collagen degradation during cancer progression, especially for promoting tumour migration and invasion. 88 These two MMPs are well expressed in human PCa and PCa cell lines 89, 90 where their expression levels positively correlate with metastatic disease. 59 In the present study, we also demonstrated, for the first time, that Glo1/MG-H1-AP/TGF-b1/Smad axis controls MMP-2 and MMP-9 expression and activity.
MicroRNAs (miRNAs) are small non-coding RNAs modulating gene expression at both post-transcriptional and post-translational levels.
Growing evidence suggests that miRNAs are important regulators of EMT 91, 92 and that loss of tumour suppressor miRNA is an established mechanism in cancer progression. 69 In particular, the tumour suppressor miR-101 is down-regulated in PCa and this attenuated expression is an important event in oncogenesis. 70 Moreover, the loss or reduced expression of miR-101 is associated with PCa cell metastasis.
69,70
Here, we demonstrated that reduced miR-101 expression, by main- Recently, a positive correlation has been described between the circulating levels of the specific AGE, CML, and PCa progression. 20 In particular, circulating CML levels were significantly higher in serum from high-grade PCa patients (Gleason grade 7-10) compared with that observed in low-grade (Gleason grade 4-6) PCa patients. Set against these results, circulating MG-derived AGEs (AP and MG-H1) levels in our PCa patient groups were lower in more aggressive than less aggressive PCa patients, suggesting that a specific pattern of AGEs may be present in the circulation of PCa patients, as it also occurs in T A B L E 2 Circulating levels of Glo1, AP, MG-H1, TGF-b1 and miR-101 in non-metastatic and metastatic prostate cancer (PCa) patients 20 These investigators examined AGE levels in serum and prostate tumour specimens and identified a potential racespecific, tumour-dependent pattern of AGE accumulation that may be indicative of disease progression. 20 Our data on the elevated levels of circulating TGF-b1 in patients with metastatic PCa are in agreement with those reported in the literature. 104, 105 Collectively, our results define a novel mechanism, based on miR-101/Glo1/MG-H1-AP/TGFb/Smad axis, in the molecular aetiology of metastatic PCa (Figure 9 ), further extending our knowledge of the mechanisms underlying PCa metastasis and suggesting miR-101 and Glo1 that orchestrate the mechanism, as novel potential therapeutic targets for metastatic PCa.
In this regard, it is significant that we show that metformin is able to inhibit Glo1, reactivate miR-101, and inhibit EMT, migration and invasion of metastatic PCa cells, opening new avenues of investigation for a novel potential mechanism, which up to now remain poorly explained, 74, 106, 107 by which this drug might control metastatic phenotype in PCa. Recently, there has been debate as to how data from in vitro studies of metformin translate into in vivo activity in clinical trials, as the majority of work in vitro has been performed with concentrations varying from 1 to 100 mmol/L, predominantly between 1 and 20 mmol/L. [108] [109] [110] [111] [112] Such concentrations would exceed levels measured in the blood of diabetic patients, 113 although many organs such as liver, kidney or small intestine are exposed to much higher concentration of metformin compared with levels measured in the serum. 114 Importantly, plasma membrane monoamine transporter or equilibrative nucleoside transporter ENT-4 facilitates metformin absorption from the lumen. 115 Other studies show the importance of the F I G U R E 8 Metformin affects PC3 cell metastatic phenotype, inhibits glyoxalase 1 (Glo1) and induces miR-101 expression. Effect of metformin on (A) Glo1 expression at transcript, protein and functional levels, evaluated by qRT-PCR, Western blotting and spectrophotometric assay, respectively, (B) miR-101 expression, evaluated by qRT-PCR, (C) epithelial-to-mesenchymal transition (EMT), evaluated by Western blot analysis of the epithelial markers E-cadherin (E-cad) and zonula occludens-1 (ZO-1) or mesenchymal markers vimentin (Vim), N-cadherin (N-cad) and Snail, (D) MMP-2 and MMP-9 expression, evaluated by Western blotting, or activity, evaluated by zymography, and (E) migration and invasion capabilities, evaluated by specific assays. Effect of miR-101 inhibition, under metformin administration, on (F) Glo1 enzyme activity, evaluated by spectrophotometry, and migration and invasion capabilities, evaluated by specific assays. Effect of Glo1 ectopic expression (pCMV-Glo1), under metformin administration, on (G) migration and invasion capabilities, evaluated by specific assays. The Western blots were obtained by the appropriate Abs. The blots were stripped off the bound Abs and reprobed with anti-b-actin to confirm equal loading. The Western blots shown are representative of three independent experiments. The histograms indicate mean AE SD of three different cultures, and each was tested in triplicate. *P < .05, **P < .01, ***P < .001 vs untreated cells expression of the OCT family to build up intracellular levels of metformin 116, 117 ; blocking OCT-1, OCT-2 and OCT-3 inhibited OCTmediated transport of metformin. 118 There is little evidence for the actual physiological concentrations of metformin achieved in normal and PCa tissues although clearly metformin could accumulate over time. Moreover, in an in vivo study that used a PCa cell xenograft model, intraperitoneal metformin treatment (1 mg/d), a dosage typically used in diabetic patients, led to a 35% reduction in tumour growth. 109 Similarly, other studies showed that treatment of cancer cells with metformin at low concentrations (30 lmol/L) decreased their invasive capacity. 119, 120 In conclusion, we demonstrate here that Glo1 sustains metastatic 
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